What AbbVie actually does
AbbVie is a biopharmaceutical company headquartered in North Chicago, Illinois. It was created in 2012 as a spin-off from Abbott Laboratories and began trading as a public company in January 2013. The name combines “Abbott” with “vie”, a nod to a Latin root meaning life.
Its portfolio covers immunology, oncology, neuroscience and aesthetics. After buying Allergan in 2020, it also owns Botox and a range of cosmetic and eye-care products.
How the business makes money
For years the company relied heavily on Humira, one of the best-selling drugs in history. When biosimilar competition arrived in the United States in 2023, AbbVie had to replace that revenue. It did so with newer immunology drugs such as Skyrizi and Rinvoq, along with growth in oncology and aesthetics.
This transition is the central question for the business: can new products grow fast enough to more than offset an ageing blockbuster?
The dividend story
AbbVie has raised its dividend every year since it separated from Abbott. Because the two companies’ records are combined, AbbVie counts as a Dividend Aristocrat, with a streak that goes back to the 1970s.
The yield tends to be higher than the market average, which attracts income investors. The payout is large relative to earnings, so it is worth watching the payout ratio and the success of new drugs, especially because pharmaceutical profits are shaped by patents.
What to keep an eye on
- Patent cliffs. Every major drug eventually loses exclusivity.
- Pricing pressure. Government drug-price rules can lower revenue.
- Debt. Acquisitions such as Allergan raised borrowing.
- Pipeline success. New launches have to deliver on expectations.
Quick take
AbbVie offers a higher yield than most large healthcare names and a long combined record of increases. Its dividend depends on how well it replaces older revenue with new products.